Bionor Pharma
Privately held Norwegian biopharmaceutical company focused on developing peptide-based therapeutic vaccines and combination immunotherapy strategies to achieve a functional cure for HIV. The company has advanced multiple vaccine candidates through preclinical and clinical development, retains ownership of its candidates, and has a stated regulatory and commercialization strategy.
Industries
Nr. of Employees
small (1-50)
Bionor Pharma
Patents
Peptides derived from viral proteins for use as immunogens and dosage reactants
US-10501499-B2
View Details
Peptides derived from viral proteins for use as immunogens and dosage reactants
US-10501499-B2
View DetailsProducts
Therapeutic HIV vaccine candidates (three candidates)
Series of peptide-based therapeutic vaccine candidates developed for HIV, including two lead candidates and an additional acquired candidate; advanced through preclinical and clinical studies with retained ownership.
Therapeutic HIV vaccine candidates (three candidates)
Series of peptide-based therapeutic vaccine candidates developed for HIV, including two lead candidates and an additional acquired candidate; advanced through preclinical and clinical studies with retained ownership.
Expertise Areas
- Therapeutic vaccine development
- HIV immunotherapy and latency-reversal strategies
- Clinical trial management for therapeutic vaccines
- Peptide vaccine R&D
Key Technologies
- Peptide vaccine platforms
- Combination therapeutic vaccine regimens
- HIV latency-reversal ("shock and kill") approaches
- Clinical trial protocol development for therapeutic vaccines
News & Updates
Original company founded in 1985 (Bionor AS).
First use of lead therapeutic vaccine candidate in humans.
Grant of a U.S. patent covering a vaccine candidate.
Initiation of research on an additional therapeutic vaccine candidate.
Company launched a therapeutic strategy combining latency reversal and immune interventions.
Publication/presentation of monotherapy trial results and successful completion of the REDUC trial.
Original company founded in 1985 (Bionor AS).
First use of lead therapeutic vaccine candidate in humans.
Grant of a U.S. patent covering a vaccine candidate.
Initiation of research on an additional therapeutic vaccine candidate.
Company launched a therapeutic strategy combining latency reversal and immune interventions.
Publication/presentation of monotherapy trial results and successful completion of the REDUC trial.